药物遗传学检测中的知情同意与隐私保护

Consent and privacy in pharmacogenetic testing.

作者信息

Robertson J A

机构信息

School of Law, The University of Texas, Austin, Texas 78705, USA.

出版信息

Nat Genet. 2001 Jul;28(3):207-9. doi: 10.1038/90032.

DOI:10.1038/90032

PMID:11431685

Abstract

The clinical use of pharmacogenetic drugs will require that a sample of a patient's DNA be tested before a drug is prescribed. Although pharmacogenetic tests pose fewer risks than genetic tests for disease mutations, they might still reveal personal information that could be used adversely to a patient's interests. Informed consent and privacy of pharmacogenetic test results may be essential in most clinical uses of pharmacogenetic drugs.

摘要

药物遗传学药物的临床应用要求在开处方前对患者的DNA样本进行检测。尽管药物遗传学检测比针对疾病突变的基因检测风险更小，但它们仍可能揭示出可能对患者利益产生不利影响的个人信息。在药物遗传学药物的大多数临床应用中，获得知情同意和保护药物遗传学检测结果的隐私可能至关重要。